Evotec SE (NASDAQ:EVO - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $7.07, but opened at $7.36. Evotec shares last traded at $7.35, with a volume of 15,314 shares.
Analyst Ratings Changes
A number of equities analysts recently weighed in on EVO shares. Royal Bank of Canada raised Evotec from a "sector perform" rating to an "outperform" rating in a research note on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised Evotec from a "hold" rating to a "buy" rating in a research note on Friday, April 12th.
Check Out Our Latest Report on Evotec
Evotec Stock Performance
The company has a 50 day simple moving average of $7.37 and a two-hundred day simple moving average of $8.71.
Hedge Funds Weigh In On Evotec
Several institutional investors and hedge funds have recently bought and sold shares of EVO. Quadrant Capital Group LLC acquired a new stake in Evotec in the 4th quarter worth approximately $25,000. Optiver Holding B.V. lifted its holdings in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock worth $945,000 after purchasing an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC acquired a new stake in Evotec in the 4th quarter worth approximately $53,931,000. Hedge funds and other institutional investors own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
